Loading
CHARM Therapeutics is a London and Cambridge company using an AI protein-modelling tool to design medicines. Its first drug, CHM-029, is a menin inhibitor for acute myeloid leukaemia, built to keep working when the leukaemia becomes resistant to the first menin inhibitors.
CHARM Therapeutics Ltd has offices at Pancras Square in London and on the Babraham Research Campus near Cambridge. It designs small molecules with DragonFold, its protein-ligand co-folding platform, and its lead programme CHM-029 is a menin inhibitor designed to mimic the binding of KMT2A to menin and to retain potency against the menin resistance mutations described with first-generation inhibitors. The company names Laksh Aithani and David Baker as co-founders. In September 2025 it closed an oversubscribed USD 80 million Series B co-led by New Enterprise Associates and SR One, with OrbiMed, F-Prime, Khosla Ventures and NVIDIA participating, and it states it has raised more than USD 150 million in total. Its first registered cancer trial, NCT07751991, a phase 1/2 first-in-human study of CHM-029 in relapsed or refractory acute myeloid leukaemia with NPM1 mutations or KMT2A or NUP98 rearrangements at sites in the United States and United Kingdom, was posted on ClinicalTrials.gov in August 2026; the company announced in October 2026 that the first cohort had been dosed and fully enrolled.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Co-led by New Enterprise Associates and SR One, with OrbiMed, F-Prime, Khosla Ventures and NVIDIA | 2025 | $80M | charmtx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Menin inhibitors, NPM1 mutation, KMT2A (MLL) rearrangement, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
Shares Menin inhibitors, NPM1 mutation, KMT2A (MLL) rearrangement, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
Shares NPM1 mutation, KMT2A (MLL) rearrangement, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Menin.
Shares NPM1 mutation, KMT2A (MLL) rearrangement, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Menin.
Shares NPM1 mutation, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Menin, Acute myeloid leukaemia.
Shares Menin inhibitors, NPM1 mutation, KMT2A (MLL) rearrangement, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia.
Shares NPM1 mutation, KMT2A (MLL) rearrangement, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Menin.
Shares F-Prime Capital, OrbiMed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/